We were initially surprised by reports of ECP’s effectiveness in BOS patients, given that previous studies have demonstrated that ECP stimulates TGF-β protein expression along with the expansion of Foxp3+CD4+ T cells (15). The gene discussed is TGFB1; the disease is Buschke-Ollendorff syndrome.